Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101114 · ClinicalTrials.gov registry record · Phase 2
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00101114: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00101114 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101114, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa work better by making tumor cells more sensitive to the drug
Interventions
- OTHER laboratory biomarker analysis
- DRUG sorafenib tosylate
- BIOLOGICAL recombinant interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101114
The ClinicalTrials.gov registry entry for NCT00101114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00101114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00101114 about?
NCT00101114 is a clinical study titled "Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer". This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth ...
What is the current status of trial NCT00101114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2004-09.
What interventions are being tested in trial NCT00101114?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sorafenib tosylate (DRUG), recombinant interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00101114?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.